Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Innocoll Technologies Premier Research Group plc |
---|---|
Information provided by: | Innocoll Technologies |
ClinicalTrials.gov Identifier: | NCT00749749 |
The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op Pain Relief System.
Condition | Intervention | Phase |
---|---|---|
Pain, Postoperative |
Device: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant) Device: ON-Q PainBuster Post-op Pain relief System |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Randomized, Single-Dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy |
Enrollment: | 27 |
Study Start Date: | September 2008 |
Study Completion Date: | December 2008 |
Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
|
Device: Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)
The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
|
2: Active Comparator
Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
|
Device: ON-Q PainBuster Post-op Pain relief System
5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
|
Hysterectomy is the second most common surgery among women in the United States (US). Abdominal hysterectomy surgery may be performed to treat benign tumors, such as fibroids, heavy periods, painful periods and chronic pelvic pain. The most common route for performing hysterectomy is through an incision in the abdominal wall; however, about 20% are performed vaginally.Laparoscopic assisted vaginal hysterectomy is performed when warranted.
Bupivacaine is a local anesthetic (pain medication) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cattle tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.
The ON Q system consists of 1 elastometric pump with a fill volume of 270 mL containing 0.25% bupivacaine; 1 soaker catheter measuring 12.5 cm in size; and a fill port, tubing, clamp, filter and flow restrictor. The pump provides positive pressure and is portable. It may be attached to the patient's dressing or placed in a carrying pouch. The catheter is inserted directly into the surgical wound providing a continuous flow of bupivacaine into the wound. A capillary flow restricting orifice located at the end of the tubing controls the flow rate.
This study will compare the total narcotic use in patients with the CollaRx Bupivacaine Implant with the total narcotic use in patients with the ON Q PainBuster Post op Pain Relief System after abdominal hysterectomy.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Has planned an elective total abdominal hysterectomy for reasons other than malignancies (such as uterine adenocarcinoma, cervical cancer or leiomyosarcoma) to be performed according to standard surgical technique using a standard incision and under general anesthesia with the following caveats:
Exclusion Criteria:
United States, Florida | |
Visions Clinical Research | |
Boynton Beach, Florida, United States, 33472 |
Study Director: | David Prior | Innocoll Technologies |
Responsible Party: | Innocoll Technologies ( David Prior ) |
Study ID Numbers: | INN-CB-005 |
Study First Received: | September 8, 2008 |
Last Updated: | March 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00749749 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Abdominal Hysterectomy Postoperative pain |
Signs and Symptoms Postoperative Complications Central Nervous System Depressants Anesthetics Bupivacaine |
Pain Peripheral Nervous System Agents Anesthetics, Local Pain, Postoperative |
Physiological Effects of Drugs Anesthetics Central Nervous System Depressants Pain Anesthetics, Local Pharmacologic Actions Signs and Symptoms Pathologic Processes |
Postoperative Complications Sensory System Agents Therapeutic Uses Bupivacaine Peripheral Nervous System Agents Central Nervous System Agents Pain, Postoperative |